Whereas AURKA, BIRC5, CHEK1, KIF11, PLK1 and the proteasome are currently evaluated in clinical trials or were preclinically examined by the PPTP and other groups [10, 24-28], AURKB inhibition was only suggested to be a potential target for NB tumor initiating cells [29] but has not been advanced to in vivo testing in neuroblastoma. The gene discussed is BIRC5; the disease is neuroblastoma.